Processa Pharmaceuticals, Inc. — Director's Dealing 2023

Apr 13, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2023-04-11

Reporting Person: Young David (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-04-11	Common Stock	P	20000	$0.52	Acquired	370424	Direct
2023-04-12	Common Stock	P	20000	$0.45	Acquired	390424	Direct
2023-04-13	Common Stock	P	20000	$0.48	Acquired	410424	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	619677	Indirect
Common Stock	215703	Indirect
Common Stock	370887	Indirect

Footnotes

F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.49 to $0.53, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.44 to $0.51, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.